"The Champagne should probably be kept on ice, at least until the two presidents put pen to paper," said state-owned media China Daily.Traderead more
U.S. stock index futures turned lower after China said it needed to have further discussions before it would sign off on the so-called phase one trade deal President Trump...US Marketsread more
Analysts say the partial U.S.-China trade deal doesn't touch on thorny issues plaguing both sides, and warn talks could break down again.World Economyread more
Economists polled by Reuters had expected Chinese exports denominated in the U.S. dollar to fall by 3% and imports to decline by 5.2% in September, compared to a year ago.China Economyread more
Boeing's board removed CEO Dennis Muilenburg as chairman amid the fall out of two 737 Max crashes that killed 346 people.Aerospace & Defenseread more
The U.K. and EU are gearing up for what could be the busiest week in British politics since June 2016.Europe Politicsread more
The U.S. had plans to hike duties on at least $250 billion in Chinese goods to 30% from 25% on Tuesday. Despite the partial trade deal, some banks on Sunday wrote that tariff...Marketsread more
"It seems like what the two leaders have done is try to set some of the thorny political issues to the side," said Dhruva Jaishankar, director of the U.S. Initiative at the...Asia Politicsread more
Beijing will be opening up its financial industry to foreign ownership from January, namely in the areas of futures, mutual funds and securities.China Economyread more
The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
(Adds details from Caligan's filing, background on Amag)
Sept 20 (Reuters) - Camber Capital Management on Friday unveiled a stake of about 13% in Amag Pharmaceuticals Inc and said it intends to discuss the drugmaker's board composition with shareholders, weeks after an activist investor called for a board shake-up.
Caligan Partners, which owns 10.3% stake in the company, earlier this month sought shareholders' consent on its call for removal of four directors from Amag's board.
The drugmaker in June won U.S. approval for its therapy to restore sexual desire in premenopausal women, yet two months later lowered its full-year revenue expectations, hurt by dismal sales in its women's health segment.
On Friday, Camber reported a 12.9% stake in Amag as of Sept. 20 and said the company's shares were undervalued, but added that it currently did not have a proposal for the drugmaker. (http://bit.ly/2kHF19L)
Camber said it may further engage in discussions with Amag's management aimed at enhancing shareholder value, including discussions about potential deals and other strategic alternatives.
Amag said in an emailed statement that it valued constructive discussions with its shareholders.
It has in the past said Caligan's actions are not in the best interest of the company and its shareholders.
Camber did not respond to Reuters request for additional details.
In Caligan's September filing, the shareholder said it believed Amag could be worth more than $30 per share, which is more than double the company's current share prices.
Caligan had said Amag should conduct a review of its alternatives, including separating its women's health products from its treatments for other disorders.
Amag last traded above $30 per share in early January 2017 and its shares were as high as $77.73 at their peak in 2015.
The company's shares were up 10% at $13.27 on Friday.
(Reporting by Manas Mishra and Anuron Kumar Mitra in Bengaluru; Editing by Shinjini Ganguli)